Delta-19 is composed of genetically modified live attenuated vaccine strains that express immunogenic antigens of SARS-CoV-2 (the virus responsible for Covid-19) and influenza viruses. The poster presentation will provide data on the development of Delta-19 and preclinical data demonstrating high levels of neutralizing antibodies for SARS-CoV-2 and influenza antigens, and protection against wild-type challenge in the ferret model.
Details of the presentation are as follows:
Presentation Title: Development of a SARS-CoV-2/Influenza Live Attenuated Intranasal Vaccine
Authors: Alaura Hoag, Matthew Baer, Amy Aspelund, Markus Wolschek, Manfred Reiter, and Thomas Muster
Presenting Author: Alaura Hoag, Vivaldi Biosciences
Date: July 17, 2022
Time: 8:30 pm CDT
Session / Location: P15, Exhibit Hall B
About Vivaldi Biosciences
Vivaldi Biosciences develops genetically engineered intranasal vaccines for epidemic and pandemic viral respiratory diseases. The company’s lead vaccine candidates are its DeltaFLU universal influenza vaccine in Phase 2 clinical development, and Delta-19 combination Covid-19 and universal influenza vaccine in preclinical development. Vivaldi Biosciences’ vaccine candidates are based on the company’s proprietary Delta NS1 technology platform. Delta NS1 is a vaccine vector based on genetically modified influenza virus strains. Delta NS1 vaccine strains are replication-deficient and unable to form viral progeny, which makes them safe. Vivaldi Biosciences has developed a rapid, high-yield Vero-cell based manufacturing system and produced Delta NS1 vaccines under cGMP for clinical trials. Vivaldi Biosciences is a venture-backed company with operations at the Research Innovation Center at Colorado State University, Fort Collins, Colorado, and in Vienna, Austria. NGN Capital LLC is the company’s lead investor. Learn more at www.vivaldibiosciences.com, and connect with Vivaldi Biosciences on Linkedin.
Bill Wick, CEO, Vivaldi Biosciences
Tel: +1 650-400-8915